These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33346431)

  • 1. [Decreasing cardiovascular morbidity: how to improve adherence to the treatment in the translational era].
    Zhirov IV
    Ter Arkh; 2020 Oct; 92(9):49-53. PubMed ID: 33346431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.
    Maree AO; Curtin RJ; Dooley M; Conroy RM; Crean P; Cox D; Fitzgerald DJ
    J Am Coll Cardiol; 2005 Oct; 46(7):1258-63. PubMed ID: 16198840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of acetylsalicylic acid for the prophylaxis of cardiovascular pathology].
    Castel JM; Artaza MA; Laporte JR
    Med Clin (Barc); 1991 May; 96(18):689-91. PubMed ID: 2072775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enteric-coated aspirin: review shows similar inhibition of platelet aggregation to ordinary dispersible aspirin.
    Cardiovasc J S Afr; 2007; 18(1):41, 43. PubMed ID: 17392997
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin.
    Hirata Y; Kataoka H; Shimura T; Mizushima T; Mizoshita T; Tanida S; Kamiya T; Joh T
    Scand J Gastroenterol; 2011 Jul; 46(7-8):803-9. PubMed ID: 21501103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABSORPTION AND METABOLISM OF ASPIRIN ADMINISTERED IN ENTERIC-COATED TABLETS.
    LEONARDS JR; LEVY G
    JAMA; 1965 Jul; 193():99-104. PubMed ID: 14304376
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of food on the absorption of acetylsalicylic acid from enteric-coated dosage forms.
    Bogentoft C; Carlsson I; Ekenved G; Magnusson A
    Eur J Clin Pharmacol; 1978 Dec; 14(5):351-5. PubMed ID: 32046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs.
    Takada M; Fukumoto K; Shibakawa M
    J Clin Pharm Ther; 2004 Apr; 29(2):183-7. PubMed ID: 15068408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [THE MORBIDITY OF POPULATION OF THE RUSSIAN FEDERATION: GEOGRAPHIC CHARACTERISTICS].
    Semenov VY
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2015; (6):6-9. PubMed ID: 27116829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption of acetylsalicylic acid from enteric-coated tablets in relation to gastric emptying and in-vivo disintegration.
    Bogentoft C; Alpsten M; Ekenved G
    J Pharm Pharmacol; 1984 May; 36(5):350-1. PubMed ID: 6145780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Albyl--Neo-Albyl].
    FROLUND A
    Ugeskr Laeger; 1963 Jan; 125():128-31. PubMed ID: 13945782
    [No Abstract]   [Full Text] [Related]  

  • 14. The Fight Against CVD in a Region of the Russian Federation.
    Galyavich AS; Vafin AY; Ziganshina LE
    Glob Heart; 2016 Dec; 11(4):445-446. PubMed ID: 27938838
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current trends of cardiovascular morbidity and mortality of children in Russian Federation. Structure of cardiac pathology in childhood].
    Shkol'nikova MA; Osokina GG; Abdulatipova IV
    Kardiologiia; 2003; 43(8):4-8. PubMed ID: 14593375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [RISKS IN THERAPY. GASTRODUODENAL LESIONS CAUSED BY ACETYLSALICYLIC ACID AND THEIR PROPHYLAXIS].
    LENTINI T; STOCCHI F
    Clin Ter; 1964 Apr; 29():3-31. PubMed ID: 14145523
    [No Abstract]   [Full Text] [Related]  

  • 17. Aspirin--a national survey V: Determination of aspirin and impurities in enteric coated tablets and suppository formulations and in vitro dissolution of enteric coated tablets.
    Kirchhoefer RD; Jefferson E; Flinn PE
    J Pharm Sci; 1982 Sep; 71(9):1049-52. PubMed ID: 7131273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of weight and enteric coating on aspirin response in cardiovascular patients.
    Peace A; McCall M; Tedesco T; Kenny D; Conroy RM; Foley D; Cox D
    J Thromb Haemost; 2010 Oct; 8(10):2323-5. PubMed ID: 20653839
    [No Abstract]   [Full Text] [Related]  

  • 19. Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
    Packard KA; Hilleman DE
    Cardiovasc Ther; 2016 Dec; 34(6):415-422. PubMed ID: 27473898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pathology of the circulatory system in officers of the Naval Fleet: an analysis of the trends and means for decreasing morbidity].
    Emel'ianenko VM
    Voen Med Zh; 1997 May; 318(5):54-6. PubMed ID: 9254488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.